Feature | November 01, 2013

Study Demonstrates Accuracy of Noninvasive CT-FFR in Evaluating CAD Patients

CT FFR, HeartFlow

HeartFlow's CT-FFR software uses supercomputing algorithms to calculate the flow of blood through a lesion in part by tracking the speed of the CT iodine contrast.

CT FFR, HeartFlow

HeartFlow's CT-FFR software showing a coronary artery tree created from a CT scan showing the FFR for a lesion.

November 1, 2013 — Clinical trial results demonstrated that a noninvasive coronary computed tomography angiography (CTA)-based test accurately assesses coronary artery disease (CAD) with results closely matching those of invasively measured fractional flow reserve (FFR), and may inform potential revascularization treatment options, including angioplasty and coronary artery bypass surgery (CABG), better than current methods. The findings of the HeartFlowNXT trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2013).
 
Current guidelines for the management of stable CAD recommend non-invasive ischemia testing such as treadmill testing, single photon emission computed tomography (SPECT), stress echocardiography or cardiac magnetic resonance before invasive coronary angiography (ICA) or coronary revascularization is considered. An invasive test, FFR, is considered the gold standard for lesion-specific coronary revascularization decisions in patients with stable CAD. 
 
However, the current noninvasive testing options such as treadmill testing, SPECT and stress echocardiography correlate poorly to FFR, and thus selection of patients for invasive angiography and coronary revascularization is often inaccurate.
 
The HeartFlowNXT trial was a blinded, prospective core lab adjudicated trial that investigated FFR-CT, a new, noninvasive FFR calculation derived from CTA images and using high-performance computing to create a 3-D map of the coronary arteries showing locations of obstructions and FFR-CT values.
 
The primary study objective was to compare per-patient diagnostic performance of FFR-CT compared to coronary CTA alone for the diagnosis of at least one hemodynamically significant stenosis using direct measurement of FFR (? 0.8) as the reference standard. The trial also measured per-vessel and per-patient diagnostic accuracy, sensitivity and specificity as well as positive and negative predictive values of FFR-CT.
 
The prospective study enrolled 254 patients scheduled to undergo non-emergent clinically indicated invasive angiography due to suspected CAD. 
 
The FFR-CT data matched closely with invasively measured FFR. The area under the receiver operating characteristic curve (AUC) for FFR-CT (? 0.8) was 0.82 versus 0.63 for coronary CTA (p < 0.0001) with invasive FFR as the reference standard. Per-patient sensitivity and specificity were 86 percent and 79 percent for FFR-CT versus 94 percent and 34 percent for coronary CTA and 91 percent and 51 percent for invasive coronary angiography (lumen reduction > 50 percent).
 
“Fractional flow reserve non-invasively calculated from coronary CTA data sets matches closely with invasively measured FFR and allows for identification of patients with hemodynamically significant coronary lesions with good accuracy. When compared to both coronary CTA and ICA, FFR-CT led to a significant reduction in the proportion of false-positive results,” said Bjarne Nørgaard, M.D., Ph.D., Aarhaus University Hospital, Denmark and lead investigator of the study. “The addition of FFR-CT to coronary CTA allows for a comprehensive anatomic and functional assessment of coronary artery disease.”
 

Limits of the Current Technology

CT-FFR may one day eliminate the need to refer patients for diagnostic catheter angiographies. However, today, users of the HeartFlow technology say it requires sending the CT DICOM dataset to the company in California. It then takes the supercomputing power of the HeartFlow computer system about a day to process the data and render a report. While this may eliminate CT-FFR's use for acute chest pain patients, it offers an option for patients considering elective PCI. Coronary CT experts say computing speed and power doubles every couple years, which will eventually enable CT-FFR to be processed onsite in minutes, instead of days or hours. 

For more information: www.crf.org

Related Content

TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data
News | Heart Valve Technology| September 19, 2016
Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at...
EBR Systems, FDA, WiSE Technology, Wireless Stimulation Endocardially, SOLVE-CRT study

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional cardiac resynchronization therapy (CRT) in heart failure patients. Graphic courtesy of Business Wire.

News | Cardiac Resynchronization Therapy Devices (CRT)| September 15, 2016
EBR Systems Inc. announced the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption...
News | Cardiac Diagnostics| September 13, 2016
September 13, 2016 — Results from a new study suggest that small molecules known as microRNAs may be part of the path
News | Cardiac Diagnostics| September 13, 2016
September 13, 2016 — Findings from a small...
News | Cardiac Diagnostics| September 12, 2016
A Saint Louis University researcher has received a grant to study the effects of treating post-traumatic stress...
Overlay Init